---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-020390"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2025-10-31T23:59:59+00:00"
generated_at: "2026-05-17T01:08:40.319961+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics sells 75% stake in Nova Cell subsidiary for $6M; expects $0.5M annual cost savings

## Summary
- Sold 22.5M shares (100% of its Nova Cell ownership) for $6M; consideration includes debt cancellation of ~$1.2M and deferred payments.
- Nova Cell ceases to be a subsidiary; Calidi expects $0.5M/year in G&A expense reductions.
- Company retains cell lines for own use; Nova Cell assumes certain liabilities and is prohibited from oncolytic virus uses.
- Calidi also terminates prior IP assignment agreement with Nova Cell.

## SEC filing metadata
- accession: 0001493152-25-020390
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2025-10-31T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 1.02, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315225020390/0001493152-25-020390-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315225020390/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-020390
- JSON: https://secwatch.observer/filing/0001493152-25-020390.json
- Plain text: https://secwatch.observer/filing/0001493152-25-020390.txt

## Source-grounded claims
- claim_id: ab42314f82f607e16e01a32a702a23fc7be63c74
  claim: Calidi Biotherapeutics, Inc. completed a disposition involving Nova Cell, Inc. for $6,000,000 (closed 2025-10-27).
  evidence_excerpt: On October 27, 2025, Calidi Biotherapeutics, Inc. (the “Company”) entered into that certain Stock Repurchase Agreement (the “SRA”) and Material Purchase Agreement (the “MPA” and together with the SRA the “Agreements”), with its majority owned subsidiary, Nova Cell, Inc. (“Nova Cell”). Pursuant to the SRA, the Company sold and transferred 22,500,000 shares of Nova Cell common stock (the “Repurchased Shares”), which represents 75% of the equity interest in Nova Cell and 100% of the Company’s ownership of Nova Cell, for a purchase price of $6,000,000 (the “Purchase Price”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000149315225020390/0001493152-25-020390-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.